AstraZeneca and Amgen drug Tezspire met the goals of a Phase 3 test in eosinophilic esophagitis (EoE), a chronic disorder whose only approved biologic therapy is Sanofi’s Dupixent. An approval for Tezspire in EoE would be its third indication, bolstering sales of the blockbuster product. The post AstraZeneca, Amgen Drug Moves Closer to Competing With Dupixent in a New Indication appeared first on MedCity News.

Datavant launched a new provider exchange platform, which replaces fax-based record requests with a digital workflow. It aims to give care teams real-time visibility into request status while easing the administrative burden on clinical staff. The post Datavant’s New Platform Could Cut Record Retrieval Time from Days to Hours appeared first on MedCity News.

It’s time we reignite treatment development for sepsis and other immune-mediated conditions that strike when patients are most vulnerable.  The post Precision Medicine Transformed Oncology —It’s Time to Do the Same for Sepsis appeared first on MedCity News.

Consumer drug platforms and how they fit into the rise of the consumer in healthcare will be part of the conversation at INVEST Digital Health, scheduled for October 29 in Dallas. Register today! The post What Do the Latest Iteration of Consumer Drug Platforms Offer? appeared first on MedCity News.

Onos Health’s Series A funding round was led by Costanoa, with support from Flare Capital Partners and CVS Health Ventures. The post Onos Health Raises $17M to Expand AI-Powered Behavioral Health Platform appeared first on MedCity News.

Boston Scientific disclosed a cyberattack disrupting its global IT systems and order shipping capabilities, with the company unable to provide a timeline for when normal operations will resume. The disclosure adds the medical device giant to a growing list of medtech companies — including Stryker, Medtronic and Abbott — hit by major cyberattacks this year. The post Cyberattack Disrupts Boston Scientific’s Operations: 7 Things to Know appeared first on MedCity News.

FDA approval of Revolution Medicines’ daraxonrasib, brand name Rasonque, makes the molecule the first RAS inhibitor approved for treating pancreatic adenocarcinoma, the most common type of pancreatic cancer. The speedy regulatory nod specifically covers advanced cases of this type of cancer, which has had limited treatment options. The post Revolution Medicines Receives Landmark FDA Drug Approval in Pancreatic Cancer appeared first on MedCity News.

Health-tech pilots don’t usually fail because the product is bad. They fail because the system was never wired to absorb it. The post Stop Pitching the Institute — Pitch the Stack appeared first on MedCity News.

A new class action lawsuit accuses Oura of overstating its smart ring’s sleep tracking accuracy, arguing the device relies on AI-generated estimates rather than the clinical measurements needed for true sleep staging. The case is reigniting questions about how much precision consumers should expect from AI-powered health wearables. The post Why Oura’s Sleep-Tracking Lawsuit Is Really About Trust appeared first on MedCity News.

Employers expect healthcare costs to rise 9.2% in 2027 as they seek ways to curb rising hospital and pharmacy costs. The post Business Group on Health: Employer Healthcare Costs Projected to Rise 9.2% in 2027 appeared first on MedCity News.

Johnson & Johnson antibody drug Imaavy expanded its label to include the treatment of warm autoimmune hemolytic anemia (wAIHA). Projected to become a blockbuster seller across multiple indications, Imaavy was first approved last year for treating generalized myasthenia gravis. The post J&J’s Imaavy Becomes First FDA-Approved Therapy for Rare Form of Anemia appeared first on MedCity News.

Here’s how finance leaders can evaluate AI investments in revenue cycle management before committing budget, and the risk exposure most vendor pitches leave out. The post Before You Sign That AI Contract: 7 Questions Every Healthcare CFO Should Ask appeared first on MedCity News.

A pharmacy error at an Ascension hospital in Nashville left four joint replacement patients injected with potassium phosphate instead of spinal anesthetic. The mix-up paralyzed one patient and harmed the other three. The Tennessee Bureau of Investigation is now probing the case. The post 4 Patients Injured After Drug Mix-Up at Ascension Hospital in Nashville appeared first on MedCity News.

Expressable has joined Amazon’s Health Benefits Connector to help families access virtual speech therapy through their insurance. The post Amazon Taps Expressable for Health Benefits Connector appeared first on MedCity News.

Hanmi Pharmaceutical’s drug is designed to activate a receptor in skeletal muscle to both increase muscle mass and reduce fat. This engineered peptide gives Roche a clinical-stage asset that addresses a different target than the other obesity drugs in its pipeline. The post Roche Gains Rights to Hanmi Obesity Drug That Reduces Fat, Preserves Muscle appeared first on MedCity News.